The Effect of Ketoconazole on Amphotericin B in a Model of Disseminated Aspergillosis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The potential of ketoconazole prophylaxis to antagonize the activity of amphotericin B against aspergilli was investigated in vitro and in neutropenic mice. Exposure of Aspergillus fumigatus (six strains) and of Aspergillus flavus or Aspergillus niger to ketoconazole resulted in a uniform increase of the minimal fungicidal activity of amphotericin B, from 0.15-0.63 mg/liter to greater than 2.5 mg/liter in a microwell assay. To test the relevance of this antagonism in vivo, we challenged neutropenic mice iv with a lethal dose of conidia from two strains of A. fumigatus and then treated the mice first with ketoconazole and then with amphotericin B or amphotericin B plus ketoconazole. Pretreatment with ketoconazole for 48 hr completely abolished the protective effect of a subsequent therapy with amphotericin B, whether ketoconazole therapy was stopped (P less than .001) or not (P less than .001). Ketoconazole given alone had no significant effect on survival. Our data show that ketoconazole not only antagonized the fungicidal activity of amphotericin B in vitro but also abolished in vivo the protective effect of the only drug shown to be useful in the therapy of aspergillosis. The clinical importance of this antagonism, which is not limited to Aspergilli in vitro, requires careful consideration before ketoconazole prophylaxis can be recommended for patients at high risk of developing invasive opportunistic fungal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pizzo, P. A., Robichaud, K. J., Gill, F. A., & Witebsky, F. G. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90594-0 · Cited by 859
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases
Denning, D. W., & Stevens, D. A. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.6.1147 · Cited by 899
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
The Impact of Culture Isolation of Aspergillus Species: A Hospital‐Based Survey of Aspergillosis
Perfect, J. R., Cox, G. M., Lee, J. Y., Kauffman, C. A., de Repentigny, L., Chapman, S. W., Morrison, V. A., Pappas, P., Hiemenz, J. W., Stevens, D. A., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/323900 · Cited by 458
“Despite concerns about antagonism of the combination of polyenes and azoles in cases of IA [80], amphotericin B and itraconazole are frequently used together successfully in clinical practice [74, 81].”
BackgroundEdwards, Jr., Bodey, G. P., Bowden, R. A., Buchner, T., de Pauw, B. E., Filler, S. G., Ghannoum, M. A., Glauser, M., Herbrecht, R., Kauffman, C. A., et al. (1997) · Clinical Infectious Diseases · doi:10.1086/514504 · Cited by 418
Overview of medically important antifungal azole derivatives
Fromtling, R. A. (1988) · Clinical Microbiology Reviews · doi:10.1128/cmr.1.2.187 · Cited by 398
Opportunistic Mycoses in the Immunocompromised Host: Experience at a Cancer Center and Review
Anaissie, E. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.supplement_1.s43 · Cited by 364
Combination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning
Chen, X., Ren, B., Chen, M., Wang, Q., Zhang, L., & Yan, G. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004975 · Cited by 279
Bench-to-bedside review: Candida infections in the intensive care unit
Méan, M., Marchetti, O., & Calandra, T. (2008) · Critical Care · doi:10.1186/cc6212 · Cited by 217
Desoubeaux, G., & Cray, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00841 · Cited by 55
“, 2013), and nitrogen mustards (Schaffner et al., 1982; Schaffner and Frick, 1985; Schaffner and Böhler, 1993) were also tested, but all of them primarily in former works.”
BackgroundCombination therapy in systemic mycosis
Polak, A. (1990) · Journal of Chemotherapy · doi:10.1080/1120009x.1990.11739020 · Cited by 35
Metadata
- Authors
- Schaffner, A., & Frick, P. G.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1985-05-01
- Volume
- 151
- Issue
- 5
- Pages
- 902-910
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2014907435
- Cited by
- 175
- References
- 1
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.